HealthLynked (HLYK) EBITDA (2016 - 2026)

HealthLynked has disclosed EBITDA across 11 years of filings, most recently posting -$774592.0 for Q1 2026.

• In Q1 2026, EBITDA rose 14.25% year-over-year to -$774592.0; the TTM figure through Mar 2026 stood at -$2.9 million (down 215.93% YoY), while the FY2025 annual figure was -$660876.0, up 43.64% from the prior year.
• EBITDA climbed to -$774592.0 in Q1 2026, from -$782896.0 in the prior quarter.
• Over the last five years, EBITDA for HLYK reached as high as $2.9 million in Q4 2023 and fell as low as -$4.1 million in Q4 2022.
• The 5-year median for EBITDA is -$1.0 million (2023), against an average of -$802046.8.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 414.21% — and 2023, when it jumped 169.35%.
• A 5-year view of EBITDA shows it stood at -$4.1 million in 2022, then jumped by 169.35% to $2.9 million in 2023, then fell by 6.59% to $2.7 million in 2024, then sank by 129.33% to -$782896.0 in 2025, then grew by 1.06% to -$774592.0 in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$774592.0, -$782896.0, and -$716499.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.